- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02241356
The Effect of Bifocals in Children With Down Syndrome
March 12, 2020 updated by: Radboud University Medical Center
Visual acuity at near improves in children with Down syndrome using bifocals
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The accommodation is consistently reduced in 50 to 100% of children with Down syndrome and does not improve with age.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Overijssel
-
Zwolle, Overijssel, Netherlands, 8025 AB
- Isala Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with Down syndrome (DS)
- Accommodation lag >0.5 Dioptres for children with DS <12 years and >0.75 Dioptres for children older than age 12 or Visual acuity at near is worse than at distance and >0.1
- Age range 2-14 years
- Speaks Dutch as the first language
- Must be verbal or able to understand instructions
- Must be able to perform a task sitting on a chair and working at a table
Exclusion Criteria:
- Visual acuity at near < 0.1
- Not able to do vision tests at age over 5
- Has worn bifocals already
- Other significant eye diseases, such as keratoconus, cataract or high myopia (>S-6.00).
- Diagnoses of any neurological, sensory or behavioural disorders such as autism, microcephaly or significant hearing loss.
- Prematurity, born premature after a pregnancy term less than 36 weeks
- Born after severe perinatal problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: single vision glasses
|
single vision glasses
|
|
Experimental: bifocals
bifocal glasses
|
bifocal glasses with an addition of 2.5 Dioptres
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
• Change from baseline in visual acuity at near measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at 16 months.
Time Frame: baseline to 12 months later
|
visual acuity is measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at baseline and at the end of the study 16 months later.
We will calculate the difference.
|
baseline to 12 months later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
• Visual acuity at near measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at 16 months.
Time Frame: after 12 months
|
visual acuity at near measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at 16 months.
|
after 12 months
|
|
• Change from baseline in visual acuity at distance measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at 16 months.
Time Frame: baseline to 12 months later
|
Visual acuity at distance is measured in decimals and in Logarithm of the Minimum Angle of Resolution (LogMAR) at baseline and at the end of the study 16 months later.
We will calculate the difference.
|
baseline to 12 months later
|
|
• Change from baseline in accuracy of accommodation response measured in Dioptres.
Time Frame: baseline to 12 months later
|
We will measure the accuracy of accommodation in Dioptres at baseline and after 16 months.
We will calculate the difference.
|
baseline to 12 months later
|
|
• Change in percentage of participants with strabismus
Time Frame: baseline to 12 months later
|
We will calculate the percentage of participants with strabismus at baseline and at the end of the study, 16 months later.
Then we can calculate the difference in percentage of participants with strabismus.
|
baseline to 12 months later
|
|
• Change in score of task readiness of the children
Time Frame: baseline to 12 months later
|
We will measure task readiness in scores of attention, reaction time, inhibition and working memory at baseline and at the end of the study 16 months later.
Then we calculate the difference in this score.
|
baseline to 12 months later
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
• Possible prognostic determinants at baseline for improvement of visual acuity at near
Time Frame: participants will be followed for the duration of 12 months, after the last included participant has been followed up for 18 months we will do this analysis
|
Applying a multivariate logistic regression model using a backward variable elimination procedure (selection criterion P < 0.05, removal criterion P < 0.10) to test a key set of independent prognostic variables (measured at baseline) for better visual acuity at near after 12 months
|
participants will be followed for the duration of 12 months, after the last included participant has been followed up for 18 months we will do this analysis
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: H HL Goossens, PhD, Radboudumc, Dept. Cognitive Neuroscience/126
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nandakumar K, Leat SJ. Bifocals in children with Down syndrome (BiDS) - visual acuity, accommodation and early literacy skills. Acta Ophthalmol. 2010 Sep;88(6):e196-204. doi: 10.1111/j.1755-3768.2010.01944.x.
- Al-Bagdady M, Stewart RE, Watts P, Murphy PJ, Woodhouse JM. Bifocals and Down's syndrome: correction or treatment? Ophthalmic Physiol Opt. 2009 Jul;29(4):416-21. doi: 10.1111/j.1475-1313.2009.00646.x. Epub 2009 May 11.
- Cregg M, Woodhouse JM, Pakeman VH, Saunders KJ, Gunter HL, Parker M, Fraser WI, Sastry P. Accommodation and refractive error in children with Down syndrome: cross-sectional and longitudinal studies. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):55-63.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
August 29, 2014
First Submitted That Met QC Criteria
September 15, 2014
First Posted (Estimate)
September 16, 2014
Study Record Updates
Last Update Posted (Actual)
March 16, 2020
Last Update Submitted That Met QC Criteria
March 12, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Intellectual Disability
- Cranial Nerve Diseases
- Ocular Motility Disorders
- Abnormalities, Multiple
- Chromosome Disorders
- Strabismus
- Down Syndrome
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
Other Study ID Numbers
- R0002308
- 2013-23 (Other Identifier: AP HM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Acuity at Near
-
Mayo ClinicNot yet recruitingVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Alcon ResearchQueensland University of TechnologyCompleted
-
Alcon ResearchCompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
Clinical Trials on single vision glasses
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Completed
-
The Hong Kong Polytechnic UniversityProcornea Nederland B.V.Completed
-
Queen's University, BelfastJohns Hopkins University; University of Michigan; Belfast Health and Social Care... and other collaboratorsRecruiting
-
Dot Glasses KenyaQueen's University, Belfast; University of Stellenbosch; Sun King; Livelihood Impact...Not yet recruitingPresbyopia Correction | Livelihoods | Visual Impairment and Blindness (Excl Colour Blindness) | Repayment Behaviour
-
nthalmic Pty LtdZhong Jing Wei Shi (Suzhou) Optical Technology Ltd.Recruiting
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Completed
-
Aristotle University Of ThessalonikiState Scholarships FoundationCompleted
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Completed
-
S-Alpha Therapeutics, Inc.RecruitingMyopiaKorea, Republic of